Potentially, a HFD strategy could be employed in the pedigrees with CHCHD10 mutations that present with cardiomyopathy (Shammas et al, 2022), whereas it is uncertain whether HFD could have beneficial effects in patients with predominantly neurological manifestations. This evidence concerns the gene CHCHD10 and cardiomyopathy.